KDM1A and gastric cancer: Currently, there are nine LSD1 inhibitors, including tranylcypromine, ORY-1001, ORY-2001, GSK-2879552, IMG-7289, INCB059872, TAK-418, CC-90011, and SP-2577, that have entered clinical trials for this finding suggests that targeting LSD1 could be a promising strategy to inhibit the growth of GC.